Europe is a 'soufflé collapsing' from the turmoil in France and Germany: David Roche
David Roche of Quantum Strategy discusses the limited impact to the Euro and French OAT spreads following the recent no-confidence vote that ousted French Prime Minister Michel Barnier. He discusses his broader outlook for Europe and what it would take for the Euro to achieve parity with the US Dollar.
FDA Accepts Roche's Columvi sBLA for Expanded Use in Lymphoma
The FDA accepts RHHBY's sBLA seeking the label expansion of Columvi to include the treatment of second-line R/R DLBCL for review.
Poseida shares triple on Tuesday, boosted by Roche collaboration
Shares of Poseida Therapeutics Inc (NASDAQ: PSTX) more than tripled this morning after Roche Holding (SWX: ROG) said it will buy the clinical-stage biopharmaceutical company for about $1.5 billion. Roche's offer values each share of Poseida Therapeutics at $9.0 that translates to a more than 200% premium on their previous close.
Roche to Acquire CAR-T Cell Therapy Focused Poseida for $1.5B
RHHBY is all set to acquire Poseida Therapeutics, Inc. and ramp up its pipeline with off-the-shelf cell therapies.
Roche's Proposed Acquisition Of Poseida Therapeutics Poised To Establish New Core Capability In Cell Therapy For Cancer And Autoimmune Diseases: Details
On Tuesday, Roche Holdings AG RHHBY agreed to acquire Poseida Therapeutics, Inc. PSTX for an equity value of approximately $1.5 billion on a fully diluted basis.
Roche records setback in phase III study of two lung cancer drugs
A Roche study into using a combination of tiragolumab and tecentriq to treat a form of lung cancer in a phase III trial did not achieve the desired success, the Swiss pharmaceuticals maker said on Tuesday.
Roche to acquire US-based Poseida Therapeutics
Roche will acquire California-based biopharmafirm Poseida Therapeutics for $9 per share at closing, for a total equity value of $1 billion, the Swiss company said on Tuesday.
RHHBY or ABBV: Which Is the Better Value Stock Right Now?
Investors looking for stocks in the Large Cap Pharmaceuticals sector might want to consider either Roche Holding AG (RHHBY) or AbbVie (ABBV). But which of these two stocks offers value investors a better bang for their buck right now?
Roche Holding AG (RHHBY) Virtual Neurology Investor Event Conference Transcript
Roche Holding AG (OTCQX:RHHBY) Virtual Neurology Investor Event Conference October 31, 2024 11:00 AM ET Company Participants Bruno Eschli – Investor Relations Azad Bonni – Senior Vice President and Global Head-Neuroscience and Rare Diseases-pRED Luka Kulic – Therapeutic Area Leader-Dementia and Expert Medical Director-Neuroscience and Rare Diseases-pRED Margherita Carboni – Indication Lead, Neurology and Clinical Development Lead-Neurology, Endocrinology and OBGYN-Roche Diagnostics Hanno Svoboda – Head-Portfolio Development and Neuroscience and Rare Diseases Conference Call Participants Richard Parkes – BNP Paribas Sachin Jain – Bank of America Colin White – UBS David Evans – Kepler Luisa Hector – Berenberg Richard Vosser – JPMorgan Rajesh Kumar – HSBC Colin White – UBS Bruno Eschli [Call Starts Abruptly] Thanks Henrik, for the introduction. Can we please go to the agenda slide, please?
'We'll see a period of haggling' over coalitions in Japan: David Roche
David Roche, strategist at Quantum Strategy, discusses the recent elections in Japan and its potential impact on markets.
Roche: Currency Headwinds Are Masking Strong Growth Trends
Roche's strong year-to-date results are masked by the strength of the Swiss franc and are also impacted by declining COVID-19 sales, but underlying growth trends are strong. Key products like Vabysmo, Ocrevus, and Phesgo are performing well. The pipeline remains healthy with upcoming readouts from mid- and late-stage trials of (among others) tiragolumab, GYM329, and fenebrutinib.
Roche CEO says there is strong underlying growth in our business
Roche CEO Thomas Schinecker joins Squawk Box after the pharma group's third-quarter sales rose 9%.
